Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ophthalmologic treatment methods using selective iNOS inhibitors

An ophthalmological, disease-based technology applied in the field of prevention and treatment of ophthalmic conditions and diseases involving excessive iNOS activity, capable of solving problems that do not include selective inhibitors of iNOS

Inactive Publication Date: 2004-12-22
PHARMACIA CORP
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although fundamental discoveries about the biochemistry and function of iNOS suggest its involvement in a variety of conditions, including ophthalmic conditions and retinal diseases, currently known methods for treating and preventing these conditions do not include the use of selective inhibitors of iNOS. treatment method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmologic treatment methods using selective iNOS inhibitors
  • Ophthalmologic treatment methods using selective iNOS inhibitors
  • Ophthalmologic treatment methods using selective iNOS inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A

[0194]

[0195] (2S,5E)-2-Amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid, dihydrochloride, monohydrate

[0196]

[0197]EX-A-1) Trimethylsilyl chloride (107.8 g, 1.00 mol) was added dropwise to a cold solution of L-glutamic acid (30.00 g, 0.20 mol) in 300 mL of methanol at 0°C. The resulting clear, colorless solution was stirred at room temperature. After 18 hours, analysis by thin layer chromatography (30% ethyl acetate in hexanes) showed no starting material remaining. The reaction was then cooled to 0°C and triethylamine (134 g, 1.33 mol) was added, forming a white precipitate. Di-tert-butyl dicarbonate (49 g, 0.23 mol) was added and the mixture was allowed to warm to room temperature. After 3 hours, the solvent was removed and 700 mL of ether was added. The solution was filtered and the filter cake was washed with an additional 500 mL of ether. The filtrate was concentrated to afford 60.8 g (>95%) of a brown oil which was used in the next step without fu...

Embodiment B

[0222]

[0223] (2S,5E / Z)-2-Amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid, dihydrochloride

[0224]

[0225] EX-B-1) To L-glutamic acid 5-methyl ester (50.00g, 0.31mol) in 400mL 1: 1H 2 To a cold (0° C.) solution in O / dioxane was added triethylamine (38.35 g, 0.38 mol) followed by di-tert-butyl dicarbonate (80.00 g, 0.37 mol). The resulting clear, colorless solution was stirred at room temperature. After 18 hours, analysis by thin layer chromatography (30% ethyl acetate in hexanes) showed no remaining starting material. With 200mL 1.0N KHSO 4 The reaction mixture was worked up with aqueous solution. The organic layer was removed and the aqueous layer was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined and washed with MgSO 4 Drying, filtration and concentration afforded 72.00 g (89%) of the desired product as a pale yellow oil.

[0226] LCMS: m / z = 284.1 [M+Na] + . 1 H NMR (CDCl 3 )? 1.50(s, 9H), 2.00(m,...

Embodiment C

[0260]

[0261] (2S,5Z)-2-Amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid, dihydrochloride

[0262]

[0263]EX-C-1) Dissolve triethyl 2-fluoro-phosphonoacetate (3.54 g, 14.6 mmol) in 20 mL of dichloromethane at 0°C, add 1,8-diazabicyclo[5.4.0] Undec-7-ene (2.4 mL, 16.4 mmol). The mixture was stirred at 0 °C for 20 minutes, resulting in an orange solution. A solution of the EX-A-3 aldehyde product (4.04 g, 11.7 mmol) was then added at 0°C, and the resulting brown mixture was stirred at room temperature overnight, at which point LCMS indicated no remaining starting material. The solvent was removed and the residue was partitioned between water (60 mL) and ethyl acetate (120 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with water (60 mL) and 10% KHSO 4 aqueous solution (60 mL), washed with MgSO 4 Dry, filter and concentrate. The crude product, 5.7 g of an orange...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Qualityaaaaaaaaaa
Qualityaaaaaaaaaa
Login to View More

Abstract

Therapeutic methods for the prevention and treatment of ophthalmologic conditions are described, the methods including administering to a subject in need thereof a selective inhibitor of inducible nitric oxide synthase.

Description

Background of the invention [0001] The present invention relates generally to methods of treatment using selective inhibitors of inducible nitric oxide synthase (iNOS), and more particularly to novel methods for the prevention and treatment of ophthalmic conditions and diseases involving excessive iNOS activity. [0002] It was discovered in the early 1980s that the relaxation of blood vessels induced by acetylcholine depends on the presence of the vascular endothelium. The endothelium-derived factor known as endothelium-derived relaxing factor (EDRF) that mediates such vascular relaxation is now known to be nitric oxide (NO). NO is a free radical gas generated in the vascular endothelium by nitric oxide synthase (NOS). The activity of NO as a vasodilator has been known for over a hundred years. In addition, NO is an active substance derived from known nitrovasodilators, including amyl nitrite and glyceryl trinitrate. Nitric oxide is also an endogenous stimulator of soluble...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D223/12A61K31/198A61K31/223A61K31/41A61K31/55A61P9/10A61P27/02A61P27/06C07D257/06
CPCA61K31/198A61K31/55A61P27/00A61P27/02A61P27/06A61P9/10A61K31/16
Inventor P·T·马宁J·R·康纳尔
Owner PHARMACIA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com